

## Supplementary materials

**Table S1. Prevalence of long-term conditions among 4428 individuals, ELSA 2016/2018**

Long-term conditions	% (N)
Arthritis	43.6 (1929)
Retinopathy/eye diseases (including diabetic retinopathy, macular degeneration, glaucoma, and cataract)	40.8 (1807)
Hyperlipidemia	39.5 (1750)
Hypertension	39.5 (1751)
CVD	22.4 (993)
Psychiatric conditions <sup>†</sup>	18.3 (810)
Lung disease <sup>†</sup>	17.1 (758)
Diabetes <sup>†</sup>	13.1 (580)
Osteoporosis (including Paget's disease and heterotopic ossification) <sup>†</sup>	10.0 (443)
Cancer	8.0 (354)
Epilepsy <sup>#</sup>	4.3 (188)
Hyperuricemia (including gout) <sup>#</sup>	2.8 (122)
Inflammatory bowel disease <sup>#</sup>	1.0 (42)
Parkinson's disease <sup>†</sup>	0.9 (39)
Dementia <sup>†</sup>	0.8 (33)

<sup>†</sup> Verified diagnosis

<sup>#</sup> Defined by recognisably specific treatments

**Table S2. Rates of COVID-19 infection or its hospitalisation by cluster, ELSA COVID-19 Substudy in 2020**

	<b>Cluster 1 Metabolic disorders</b>	<b>Cluster 2 Heterogeneous comorbidities</b>	<b>Cluster 3 CVD with complex comorbidities</b>	<b>Cluster 4 Healthiest</b>
	(N=1389) % (N)	(N=1666) % (N)	(N=596) % (N)	(N=777) % (N)
COVID-19 infection	18.7 (260)	24.4 (406)	28.2 (168)	16.9 (131)
Hospitalisation due to COVID-19 infection	0.3 (4)	0.9 (15)	1.2 (7)	0.1 (1)

**Table S3. Model fit statistics for other cluster options (N=4428)**

	2-cluster	3-cluster	4-cluster	5-cluster	6-cluster
Sample size in each cluster	3651, 777	3055, 596, 777	1389, 1666, 596, 777	425, 964, 1666, 596, 777	425, 964, 384, 1282, 596, 777
COVID-19 infection					
Log likelihood	-2278.6364	-2273.8478	-2267.5284	-2266.036	-2264.6177
AIC	4575.273	4567.696	4557.057	4556.072	4555.235
BIC	4632.834	4631.653	4627.41	4632.82	4638.379
Hospitalisation due to COVID-19 infection					
Log likelihood	-149.66496	-149.35208	-147.35708	-147.18351	-145.6499
AIC	317.3299	318.7042	316.7142	318.367	317.2998
BIC	374.8912	382.6612	387.0669	395.1155	400.4439

**Table S4. Sensitivity analyses of the associations\* between metformin use/undiagnosed diabetes and COVID-19 infection or its hospitalisation (N=4428), England 2016/2018–2020**

	COVID-19 infection		Hospitalisation due to COVID-19 infection <sup>#</sup>	
	OR (95% CIs)	P	OR (95% CIs)	P
Diabetes <sup>†</sup>				
Diagnosed with metformin	0.89 (0.67, 1.18)	0.416	0.19 (0.02, 1.46)	0.109
Diagnosed without metformin	1.13 (0.83, 1.52)	0.437	1.00	—
Undiagnosed	0.78 (0.37, 1.68)	0.532	4.80 (1.01, 22.73)	<b>0.048</b>
CVD	1.46 (1.23, 1.74)	<b>&lt;0.001</b>	1.45 (0.64, 3.30)	0.371
Lung disease	1.41 (1.17, 1.69)	<b>&lt;0.001</b>	1.52 (0.65, 3.55)	0.337
Psychiatric conditions	1.40 (1.16, 1.68)	<b>&lt;0.001</b>	0.84 (0.32, 2.22)	0.725
Arthritis	1.26 (1.08, 1.48)	<b>0.003</b>	1.13 (0.49, 2.58)	0.781
Retinopathy/eye diseases	1.39 (1.18, 1.64)	<b>&lt;0.001</b>	3.34 (1.28, 8.69)	<b>0.013</b>
Number of conditions <sup>§</sup>	1.06 (0.98, 1.15)	0.154	1.25 (0.85, 1.84)	0.251

\* Adjusted for age, gender, total wealth, alcohol consumption (a current drinker or not), self-rated weight, self-isolation, and close contact with people who tested positive

<sup>†</sup> 330 participants with diagnosed diabetes and metformin; 250 participants with diagnosed diabetes but without metformin; 43 participants with undiagnosed diabetes

<sup>#</sup> Of 27 individuals who were hospitalised, 24 had no diabetes; 1 had diagnosed diabetes and took metformin; 2 had undiagnosed diabetes

<sup>§</sup> The other remaining conditions, not including diabetes, CVD, lung disease, psychiatric conditions, arthritis, and retinopathy/eye diseases

**Table S5. Sensitivity analyses of the associations between long-term conditions or comorbidity patterns and COVID-19 infection, with a stricter definition (N=4428), England 2016/2018–2020**

	COVID-19 infection	
	OR (95% CIs)	P
Single long-term conditions <sup>†</sup>		
Diabetes	0.87 (0.66, 1.15)	0.329
CVD	1.47 (1.19, 1.82)	<b>&lt;0.001</b>
Lung disease	1.72 (1.38, 2.13)	<b>&lt;0.001</b>
Psychiatric conditions	1.14, (0.91, 1.44)	0.251
Arthritis	1.20 (0.99, 1.46)	0.069
Retinopathy/eye diseases	1.36 (1.10, 1.67)	<b>0.004</b>
Number of conditions <sup>§</sup>	1.09 (0.98, 1.20)	0.097
Comorbidity pattern <sup>*</sup>	OR (95% CIs)	P
Metabolic disorders (cluster 1)	1.01 (0.74, 1.38)	0.949
Heterogeneous comorbidities (cluster 2)	1.44 (1.07, 1.93)	<b>0.015</b>
CVD with complex comorbidities (cluster 3)	1.86 (1.32, 2.61)	<b>&lt;0.001</b>

<sup>†</sup> Fully adjusted model (Model 4)

<sup>\*</sup> Cluster 4 Healthiest as the reference group

**Table S6. Baseline characteristics between complete cases (N=4428) and samples with missing values, ELSA 2016/2018**

	Complete cases (N=4428)	Sample with missing values	
	% (N)	% (N)	Sample size
Age (years) mean (SD)	69.2 (7.9)	69.2 (8.0)	4690
Women	56.6 (2506)	56.3 (2657)	4720
Total wealth			
1 (lowest)	12.5 (553)	12.9 (597)	4637
2	15.9 (705)	16.0 (742)	
3	22.5 (998)	22.5 (1044)	
4	24.5 (1084)	24.4 (1129)	
5 (highest)	24.6 (1088)	24.3 (1125)	
Diabetes	13.1 (580)	13.2 (621)	4720
CVD	22.4 (993)	22.4 (1057)	4720
Lung disease	17.1 (758)	17.2 (811)	4720
Psychiatric conditions	18.3 (810)	18.1 (854)	4720
Arthritis	43.6 (1929)	43.6 (2060)	4720
Retinopathy/eye diseases	40.8 (1807)	40.6 (1916)	4720
Number of conditions median (IQR)	1 (2)	1 (2)	4720
Current drinker	63.4 (2807)	63.3 (2894)	4570
Self-rated over- or underweight	58.0 (2567)	57.5 (2695)	4691
Self-isolation*	32.5 (1441)	32.7 (1544)	4720
Close contact with people who tested positive*	13.8 (609)	13.3 (629)	4716

\* Data was collected in ELSA COVID-19 Substudy

Figure S1. Dendrogram of cluster analysis

